Clinical characteristics and outcome in patients with antisynthetase syndrome associated interstitial lung disease: a retrospective cohort study

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

  • Mads Lynge Jensen
  • ,
  • Anders Løkke
  • ,
  • Ole Hilberg, Department of Respiratory Diseases, Vejle Hospital, Vejle, Denmark.
  • ,
  • Charlotte Hyldgaard
  • Elisabeth Bendstrup
  • Dan Tran, Department of Respiratory Diseases, Sydvestjydsk Regional Hospital, Esbjerg, Denmark.

Background and objective: To describe the clinical characteristics including the bronchoalveolar lavage fluid (BALF) characteristics of patients with antisynthetase syndrome (AS) associated interstitial lung disease (ILD) in a tertiary ILD outpatient clinic, their medical therapy and outcome. Methods: Retrospective cohort study of patients with AS-ILD. All available data of clinical characteristics, pulmonary function tests, laboratory parameters, BALF analysis, histology, high-resolution computed tomography (HRCT) and treatment were collected from the patient files. Results and conclusions: Twelve patients with AS-ILD were identified. Mean age at diagnosis was 55 years (range 45-69), 67% were female. Mean follow-up time was 7 years. The anti-aminoacyl tRNA-synthetase antibodies presented were anti-Jo1 (n = 6), anti-PL7 (n = 3), anti-PL12 (n = 2) and anti-EJ (n = 1). HRCT patterns were mainly non-specific interstitial pneumonia (75%). Four patients had BALF-eosinophilia (two of four anti-Jo1 patients) and two anti-PL12 positive patients had BALF-neutrophilia. Two AS-ILD patients improved on rituximab (RTX) as induction treatment and three out of four patients were stabilised on RTX as maintenance treatment. Two patient obtained remission by cyclophosphamide. Four patients were stabilised on azathioprine alone or in combination with oral corticosteroids. Our cohort of AS-ILD patients showed clinical characteristics in accordance with previous reports at baseline and was comparable to other cohorts. Most patients can be stabilised with immunosuppressive treatment.

Original languageEnglish
Article number1583516
JournalEuropean Clinical Respiratory Journal
Number of pages7
Publication statusPublished - 2019

    Research areas

  • ANTIBODIES, ARTHRITIS, Antisynthetase syndrome, DERMATOMYOSITIS, POLYMYOSITIS, RITUXIMAB, SEVERITY, bronchoalveolar lavage fluid, interstitial lung diseases, polymyositis, treatments

See relations at Aarhus University Citationformats

ID: 155229152